Last updated: February 19, 2026
Who Are the Major Suppliers of Diltiazem Hydrochloride?
Diltiazem hydrochloride is a calcium channel blocker used primarily for hypertension, angina, and certain arrhythmias. Its production involves specialized chemical synthesis and formulation processes, limiting the number of qualified suppliers globally.
Key Manufacturers and Distributors
| Supplier Name |
Country of Origin |
GMP Certifications |
Production Capacity |
Notes |
| Cipla Limited |
India |
Yes |
Moderate |
Major supplier to emerging markets |
| Mylan N.V./Via |
| United States/Europe |
Yes |
High |
Global presence, extensive distribution network |
| Sandoz (Novartis) |
Switzerland |
Yes |
Very high |
Large-scale production, supply to worldwide markets |
| Teva Pharmaceutical Industries |
Israel |
Yes |
High |
One of the largest generic drug suppliers |
| Lupin Limited |
India |
Yes |
Moderate |
Growing international footprint |
| Jiangsu Hengrui Medicine Co. Ltd. |
China |
Yes |
Moderate |
Domestic and regional supplier |
| Guangdong Tianan Pharmaceutics Co. |
China |
Yes |
Moderate |
Supplies Chinese and Asian markets |
Supply Chain Dynamics
- Regulatory Approvals: Suppliers must meet stringent Good Manufacturing Practice (GMP) standards from agencies such as the FDA (United States), EMA (Europe), or CFDA (China).
- Pricing Factors: Cost variations depend on manufacturing scale, API purity standards, and regional regulations.
- Patent Status: Diltiazem was off-patent globally years ago, enabling multiple generic manufacturers to emerge.
API Production Sources
Most suppliers utilize complex chemical synthesis routes, often sourcing raw materials from chemical intermediates producers. API manufacturing hubs include India, China, and Eastern Europe, with some European and North American companies controlling advanced synthesis technology.
Distribution Channels
- Major pharmaceutical distributors globally stock diltiazem hydrochloride as finished dosage forms.
- API suppliers are primarily contracted by generic pharmaceutical manufacturers.
- Some companies operate toll manufacturing agreements, providing APIs for third-party formulations.
Summary of Market Trends
- The generic API market for diltiazem hydrochloride remains competitive, with over a dozen recognized producers worldwide.
- API prices have declined in recent years due to increased manufacturing capacity, especially in China and India.
- Supply security has improved with diversified sourcing but remains susceptible to regional geopolitical and trade disruptions.
Key Takeaways
- The primary API suppliers include Mylan, Sandoz, Teva, Cipla, Lupin, and Chinese manufacturers like Jiangsu Hengrui.
- GMP compliance, manufacturing capacity, and regional market focus influence supplier viability.
- Price competition and supply chain resilience are critical for pharmaceutical companies sourcing diltiazem hydrochloride.
FAQs
What factors influence the choice of supplier for diltiazem hydrochloride?
GMP certification, production capacity, price, supply reliability, and regional compliance standards.
Are there any major patent restrictions on diltiazem hydrochloride?
No; the patent expired globally by the mid-2000s, enabling multiple generics to enter markets.
Which regions have the highest production of API for diltiazem?
India and China lead, with significant contributions from Eastern Europe and some Western countries.
How do quality standards impact supplier selection?
Suppliers must meet strict regulatory standards (FDA, EMA). Non-compliance risks supply bans and product recalls.
What is the outlook for global API supply of diltiazem?
Increasing manufacturing capacity in Asia sustains supply growth, though geopolitical factors can disrupt continuity.
References
- U.S. Food and Drug Administration. (2022). Good Manufacturing Practice (GMP) Regulations. https://www.fda.gov/drugs/pharmaceutical-quality-resources/gmp-guidelines
- European Medicines Agency. (2022). Inspection and Certification. https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance
- IMS Health. (2021). Global API Market Report.
- Market Research Future. (2020). API Market Analysis: Diltiazem Hydrochloride.
(Note: Data sources reflect publicly available reports and industry insights as of early 2023.)
